Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3007177 | 0.89 | — | — | |
| SCHEMBL3001866 | 0.89 | ESR1 (0.38) | ESR1ESR2 | |
| SCHEMBL6788115 | 0.83 | — | — | |
| SCHEMBL3700202 | 0.80 | CTSD (0.31) | — | |
| SCHEMBL2993565 | 0.75 | CYP3A4 (0.41) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL2998095 | 0.74 | — | — | |
| SCHEMBL2998015 | 0.74 | — | — | |
| SCHEMBL18605788 | 0.74 | CYP3A4 (0.44) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL2542068 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL3662739 | 0.72 | CYP3A4 (0.43) | CYP3A4TDP1DRD1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084100-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND | APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) | 2025-03-13 | — | — | US | claimed |
| EP-4368621-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND | Applied Pharmaceutical Science, Inc. (CN) | 2024-05-15 | — | — | EP | claimed |
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | TOLREMO THERAPEUTICS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025120669-A1 | A LENTICULE, METHOD OF PREPARATION AND IMPLEMENTATIONS THEREOF | PANDORUM TECHNOLOGIES PRIVATE LIMITED (IN) | 2025-06-12 | — | — | WO | disclosed |
| US-20250084100-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND | APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) | 2025-03-13 | — | — | US | disclosed |
| US-20250057815-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-20 | — | — | US | disclosed |
| US-20250049970-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-02-13 | — | — | US | disclosed |
| US-20250034210-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20250011368-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2024-10-03 | — | — | US | disclosed |
| EP-1903394-A1 | Resist composition, resin for use in the resist composition, and pattern-forming method using the resist composition | FUJIFILM Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-1847553-A1 | METHOD FOR REMOVING METAL AND METHOD FOR PRODUCING POLYMER | NIPPON SODA CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1780224-A1 | MULTIBRANCHED POLYMERS AND PROCESS FOR PRODUCTION THEREOF | NIPPON SODA CO., LTD. (JP) | 2007-05-02 | — | — | EP | disclosed |
| EP-1553117-B1 | SOLID POLYMER ELECTROLYTE | NIPPON SODA CO (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-20060223944-A1 | Polar monomer-olefin copolymer and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2006-10-05 | — | — | US | disclosed |
| US-20060166136-A1 | Positive resist composition for immersion exposure and pattern-forming method using the same | FUJI PHOTO FILM CO., LTD. | 2006-07-27 | — | — | US | disclosed |
| EP-1684119-A2 | Positive resist composition for immersion exposure and pattern-forming method using the same | FUJI PHOTO FILM CO., LTD. (JP) | 2006-07-26 | — | — | EP | disclosed |
| US-20050256256-A1 | Block polymer of polymethoxypolyethylene glycol monomethyl methacrylate and polystyrene; LiClO4 a lithium salt as electrolyte; living copolymerization, block polymerization; excellent thermal characteristics, physical characteristics, and ionic conductivity; secondary batteries | NIPPON SODA CO., LTD (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1553117-A1 | SOLID POLYMER ELECTROLYTE | NIPPON SODA CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | SLC10A1, MAPT, SLC6A6 | CYP3A4 606/4885TDP1 763/4885DRD1 4318/4885 |
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | CYP3A4 99/4885TDP1 751/4885DRD1 3472/4885 |
| US-20250049970-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDLIM5 | CYP3A4 4882/4885TDP1 3564/4885DRD1 2629/4885 |
| US-20250084100-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND | RANBP1, RANBP2, RAN | CYP3A4 635/4885TDP1 4063/4885DRD1 665/4885 |
| US-20250011368-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDCD1LG2 | CYP3A4 4882/4885TDP1 3582/4885DRD1 2255/4885 |
| US-20250057815-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | CYP3A4 2036/4885TDP1 3121/4885DRD1 3978/4885 |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | CYP3A4 99/4885TDP1 751/4885DRD1 3472/4885 |
| US-20250034210-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDCD1LG2 | CYP3A4 4882/4885TDP1 3582/4885DRD1 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.